What is the level of liabilities of Geneuro this year?
Geneuro has a debt balance of 20.14 M EUR this year.
Geneuro Liabilities 2024
Geneuro Liabilities
20.14 M EUR
Ticker
GNRO.PA
ISIN
CH0308403085
WKN
A2AHDP
In 2024, Geneuro's total liabilities amounted to 20.14 M EUR, a 101.26% difference from the 10.01 M EUR total liabilities in the previous year.
Geneuro Aktienanalyse
What does Geneuro do?
Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Geneuro's Liabilities
Geneuro's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Geneuro's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Geneuro's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Geneuro's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Geneuro’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Geneuro stock
What were the liabilities of Geneuro compared to the previous year?
The liabilities of Geneuro have increased by 101.26% increased compared to the previous year.
What are the consequences of high debt for investors of Geneuro?
High liabilities can pose a risk for investors of Geneuro, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Geneuro?
Low liabilities mean that Geneuro has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Geneuro affect the company?
An increase in liabilities of Geneuro can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Geneuro affect the company?
A decrease in the liabilities of Geneuro can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Geneuro?
Some factors that can influence the liabilities of Geneuro include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Geneuro so important for investors?
The liabilities of Geneuro are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Geneuro take to modify the liabilities?
To change its liabilities, Geneuro can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Geneuro pay?
Over the past 12 months, Geneuro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geneuro is expected to pay a dividend of 0 EUR.
What is the dividend yield of Geneuro?
The current dividend yield of Geneuro is .
When does Geneuro pay dividends?
Geneuro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geneuro?
Geneuro paid dividends every year for the past 0 years.
What is the dividend of Geneuro?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geneuro located?
Geneuro is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geneuro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geneuro from 8/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
When did Geneuro pay the last dividend?
The last dividend was paid out on 8/26/2024.
What was the dividend of Geneuro in the year 2023?
In the year 2023, Geneuro distributed 0 EUR as dividends.
In which currency does Geneuro pay out the dividend?
The dividends of Geneuro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Geneuro
Our stock analysis for Geneuro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geneuro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
